Search Results

Tuesday’s round brings Bain Capital Life Sciences’ fundraising total to around $6.7 billion since its founding in 2016. Many of its portfolio companies have resulted in high-value exits recently, including Cerevel Therapeutics, Aiolos Bio and Jnana Therapeutics.

A new study from Bain & Company and KLAS Research shows US healthcare providers are accelerating spending on IT and software.

Venture Capital firms Atlas Venture, Bain Capital Life Sciences and RTW Investments have led a $400 million Series A for Kailera Therapeutics, the latest obesity biotech to hit the scene.

Backed by Bain Capital, Cardurion Pharmaceuticals will use the Series B funds to advance two assets for heart failure and other cardiovascular conditions.

Mariana Oncology today announced the appointment of Linda Bain as Chief Operating Officer and Chief Financial Officer.

Inc. Magazine has named trailblazing life sciences company Xenco Medical one of the best companies to work for in America.

HeartFlow, Inc. announced the close of a $215 million Series F funding round by its parent company HeartFlow Holding, Inc., led by Bain Capital Life Sciences with participation from new investor Janus Henderson Investors, and existing investors including Baillie Gifford, Capricorn Investment Group, Hayfin Capital Management, HealthCor, Martis Capital, USVP and Wellington Management.

Xilio Therapeutics, Inc. announced that it has entered into a securities purchase agreement with certain existing accredited investors, including Bain Capital Life Sciences and Rock Springs Capital.

Many biopharma professionals view smaller companies as having the best flexibility and remote work options, but that doesn’t mean their larger counterparts are failing in that area. Several professionals, including Apogee Therapeutics and Insmed executives, share their insights.